239 related articles for article (PubMed ID: 21044864)
1. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.
Montagna P; Hornyak M; Ulfberg J; Hong SB; Koester J; Crespi G; Albrecht S
Sleep Med; 2011 Jan; 12(1):34-40. PubMed ID: 20965780
[TBL] [Abstract][Full Text] [Related]
3. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole (Mirapex) for restless legs syndrome.
Med Lett Drugs Ther; 2007 Mar; 49(1257):26-8. PubMed ID: 17375031
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2006 Aug; 7(5):407-17. PubMed ID: 16815748
[TBL] [Abstract][Full Text] [Related]
6. Pramipexole: new indication. Restless legs: still no satisfactory drug treatment.
Prescrire Int; 2007 Feb; 16(87):12. PubMed ID: 17323517
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with pramipexole in the treatment of restless legs syndrome.
Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
[TBL] [Abstract][Full Text] [Related]
8. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial.
Merlino G; Dolso P; Canesin R; Cancelli I; Valente M; Gigli GL
Neuropsychobiology; 2006; 54(3):195-200. PubMed ID: 17314491
[TBL] [Abstract][Full Text] [Related]
9. Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep.
Manconi M; Ferri R; Zucconi M; Clemens S; Rundo F; Oldani A; Ferini-Strambi L
Sleep Med; 2011 Jan; 12(1):47-55. PubMed ID: 20851046
[TBL] [Abstract][Full Text] [Related]
10. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.
Inoue Y; Hirata K; Kuroda K; Fujita M; Shimizu T; Emura N; Uchimura N; Kagimura T; Sha K; Nozawa T
Sleep Med; 2010 Jan; 11(1):11-6. PubMed ID: 19962941
[TBL] [Abstract][Full Text] [Related]
12. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
[TBL] [Abstract][Full Text] [Related]
13. Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS.
Varga LI; Ako-Agugua N; Colasante J; Hertweck L; Houser T; Smith J; Watty AA; Nagar S; Raffa RB
J Clin Pharm Ther; 2009 Oct; 34(5):493-505. PubMed ID: 19744006
[TBL] [Abstract][Full Text] [Related]
14. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndrome patients with low serum ferritin.
Lee CS; Lee SD; Kang SH; Park HY; Yoon IY
Eur J Neurol; 2014 Feb; 21(2):260-6. PubMed ID: 24267148
[TBL] [Abstract][Full Text] [Related]
16. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
Bassetti CL; Bornatico F; Fuhr P; Schwander J; Kallweit U; Mathis J;
Swiss Med Wkly; 2011; 141():w13274. PubMed ID: 22101745
[TBL] [Abstract][Full Text] [Related]
17. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
[TBL] [Abstract][Full Text] [Related]
18. Restless legs syndrome: differential diagnosis and management with pramipexole.
Brindani F; Vitetta F; Gemignani F
Clin Interv Aging; 2009; 4():305-13. PubMed ID: 19750232
[TBL] [Abstract][Full Text] [Related]
19. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
Saletu M; Anderer P; Saletu-Zyhlarz G; Hauer C; Saletu B
Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):185-94. PubMed ID: 12242580
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
